Incomplete Freund’s adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment

by Karlyn E Pollack, Alexander F Koeppel, Samuel J Young, Katia Sol-Church, Craig L Slingluff Jr
Published 2020-06-01

Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma

by Mouadh Benamar, Fadila Guessous, Kangping Du, Patrick Corbett, Joseph Obeid, Daniel Gioeli, Craig L. Slingluff Jr, Tarek Abbas
Published 2016-08-01

Heterogeneity in tertiary lymphoid structure B-cells correlates with patient survival in metastatic melanoma

by Ileana S Mauldin, Nolan A Wages, Max O Meneveau, Kevin T Lynch, Samuel J Young, Craig L Slingluff Jr, Victor H Engelhard
Published 2021-06-01

MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma

by Victor H Engelhard, Rebecca C Obeng, Kara L Cummings, Angela L Ambakhutwala, Amanda Lulu, Paisley Myers, Keira E Mahoney, Donald F Hunt, Craig L Slingluff, Jr
Published 2020-06-01

Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund’s adjuvant, cyclophosphamide, and polyICLC (Mel63)

by Kelly T Smith, Nikole Varhegyi, Nolan A Wages, Emily H Hall, Kathleen Haden, Craig L Slingluff, Jr., Lynn T Dengel, Anna Dickinson, Caroline Reed, Elizabeth M Gaughan, Varinder Kaur, Nadejda V Galeassi
Published 2021-01-01